Marco Caremi

Chief Executive Officer at

Newron Sweden AB

69 year

28 connections

Health Technology

Consumer Services

Commercial Services

Profile

Marco Caremi is currently working as a Director at Hunter-Fleming Ltd., President & Director at Newron Pharmaceuticals US, Inc., and Co-General Manager at Newron Sweden AB. Previously, he worked as a Director-Business Development at Schwarz Pharma SpA from 1998 to 2002, Sales Representative & Sales Specialist at Polifarma SpA, Manager-Business Development at Schering-Plough SpA from 1996 to 1998, and Executive Vice President-Business Development at Newron Pharmaceuticals SpA from 2002 to 2023.
He completed his undergraduate degree from the University of Milan.

Marco Caremi active positions

Companies	Position	Start
Hunter-Fleming Ltd. Hunter-Fleming Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products	Director/Board Member	-
Newron Sweden AB Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders	Chief Executive Officer	-
Newron Pharmaceuticals US, Inc. Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease.	President	-

All active positions of Marco Caremi

Former positions of Marco Caremi

Companies	Position	End
NEWRON PHARMACEUTICALS S.P.A.	General Counsel	01/01/2012
Schwarz Pharma SpA	Corporate Officer/Principal	01/01/2002
Schering-Plough SpA	Corporate Officer/Principal	01/01/1998
Polifarma SpA Polifarma SpA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for central nervous system, gastroenterology, ophthalmology, cardiology & infectious diseases	Sales & Marketing	-

See the detail of Marco Caremi's experience

Training of Marco Caremi

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Marco Caremi's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	8
Hunter-Fleming Ltd. Hunter-Fleming Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products	Health Technology
Newron Pharmaceuticals SpA Newron Pharmaceuticals SpA Pharmaceuticals: MajorHealth Technology Develops and sells novel therapies central & peripheral nervous system	Health Technology
Newron Sweden AB Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders	Health Technology
University of Milan University of Milan Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Polifarma SpA Polifarma SpA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for central nervous system, gastroenterology, ophthalmology, cardiology & infectious diseases	Health Technology
Schering-Plough SpA
Schwarz Pharma SpA
Newron Pharmaceuticals US, Inc. Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease.	Commercial Services